Device Trial Radar · NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24,000
Planned (sponsor's estimate)
Start
Jun 18, 2025
Primary completion
Jan 31, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Conditions
- Bladder Carcinoma
- Breast Carcinoma
- Colorectal Carcinoma
- Esophageal Carcinoma
- Gastric Carcinoma
- Liver Carcinoma
- Lung Carcinoma
- Malignant Solid Neoplasm
- Ovarian Carcinoma
- Pancreatic Carcinoma
- Prostate Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo blood collection
Device UsageDevice
Evaluation of MCD tests
Electronic Health Record ReviewOther
Obtain health data
Multi-Cancer Early Detection TestProcedure
Undergo Shield MCD test
Multi-Cancer Early Detection TestProcedure
Undergo Avantect MCD test
Questionnaire AdministrationOther
Study specific questionnaires
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of enrollment onto studyTime frame: At time of randomization
- Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receiptTime frame: Up to 3 years
- Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time pointTime frame: Up to 2 years
3 more outcomes with a free account
Locations
49 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente-Division of Research
Pleasanton, California · Recruiting
Naval Medical Center -San Diego
San Diego, California · Recruiting
Keefe Memorial Hospital
Cheyenne Wells, Colorado · Recruiting
46 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.